Condition: Esophageal Cancer · Sponsor: AHS Cancer Control Alberta
This study aims to show that the addition of carboplatin and paclitaxel chemotherapy to a palliative course of external beam radiation treatment improves both dysphagia relief and patient quality of life in patients with unresectable esophageal cancer.
This description comes directly from the study's public registry record.
Marilyn David · 5872315492 · marilyn.david@cancercarealberta.ca
Amy Abel · amy.abel@albertahealthservices.ca
Always discuss trial participation with your own doctor first.
| Tom Baker Cancer Centre | Calgary, Alberta, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02297217